Cargando…

2521. Prevalence and Associated Factors of Protective Antibody Responses against Diphtheria, Tetanus, and Pertussis among HIV-Infected Thai Adolescents Stable on Combination Antiretroviral Treatment

BACKGROUND: To assess the prevalence and associated factors of protective antibodies against diphtheria, tetanus, and pertussis among HIV-infected adolescents stable on combination antiretroviral treatment (cART). METHODS: A multicenter seroprevalence study was conducted. Perinatally HIV-infected Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sudjaritruk, Tavitiya, Kanjanavanit, Suparat, Prasarakee, Chanidapa, Sarachai, Saowalak, Taweehorm, Wanvisa, Aurpibul, Linda, Sintupat, Kamolrawee, Khampan, Ratchaneekorn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810816/
http://dx.doi.org/10.1093/ofid/ofz360.2199
_version_ 1783462333081714688
author Sudjaritruk, Tavitiya
Kanjanavanit, Suparat
Prasarakee, Chanidapa
Sarachai, Saowalak
Taweehorm, Wanvisa
Aurpibul, Linda
Sintupat, Kamolrawee
Khampan, Ratchaneekorn
author_facet Sudjaritruk, Tavitiya
Kanjanavanit, Suparat
Prasarakee, Chanidapa
Sarachai, Saowalak
Taweehorm, Wanvisa
Aurpibul, Linda
Sintupat, Kamolrawee
Khampan, Ratchaneekorn
author_sort Sudjaritruk, Tavitiya
collection PubMed
description BACKGROUND: To assess the prevalence and associated factors of protective antibodies against diphtheria, tetanus, and pertussis among HIV-infected adolescents stable on combination antiretroviral treatment (cART). METHODS: A multicenter seroprevalence study was conducted. Perinatally HIV-infected Thai adolescents (11–25 years) who had previous evidence of severely immune suppression (CD4 < 15% or < 200 cells/mm(3)), were currently stable on cART (CD4 > 350 cells/mm(3) for > 6 months or CD4 > 200 cells/mm(3) with viral suppression [VS; HIV RNA < 50 copies/mL] for > 12 months) and had completed a 5-dose series of diphtheria, tetanus, whole cell pertussis (DTwP) vaccine during childhood were enrolled. Adolescents who received immunosuppressive agents or blood components within 6 months were excluded. Protective antibodies for diphtheria, tetanus, and pertussis were defined as diphtheria toxoid IgG ≥ 0.1 IU/mL, tetanus toxoid IgG ≥ 0.1 IU/mL, and anti-pertussis toxin IgG ≥ 5 IU/mL, respectively. Logistic regression analysis was performed to identify factors associated with protective antibody response to each antigen. RESULTS: Of 150 adolescents, 47% were male, a median age was 19 years. Forty (27%) and 0 (0%) adolescents had ever received tetanus, diphtheria (Td) or tetanus, diphtheria, acellular pertussis (Tdap) vaccine during adolescence, respectively. A median duration since the last dose of DTwP/Td vaccine was 12 years. At enrollment, 67% of adolescents were on NNRTI-based cART regimens, a median cART duration was 13 years. A median CD4 was 29%, and 90% had VS. Prevalence of protective antibodies against diphtheria, tetanus, and pertussis were 37%, 82%, and 52%, respectively. Proportion of adolescents with protective antibodies and geometric mean concentrations of antibodies to all antigens declined over time after the last immunization (Figures 1–3). Associated factors of protective antibodies to diphtheria, tetanus and pertussis are shown in Table 1. CONCLUSION: Although having completed a 5-dose series of DTwP during childhood, significant proportion of our perinatally HIV-infected adolescents had no protective antibodies to those antigens, particularly diphtheria and pertussis, when entering adolescence. Tdap vaccination is a crucial strategy to prevent such diseases in the future. [Image: see text] [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810816
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68108162019-10-28 2521. Prevalence and Associated Factors of Protective Antibody Responses against Diphtheria, Tetanus, and Pertussis among HIV-Infected Thai Adolescents Stable on Combination Antiretroviral Treatment Sudjaritruk, Tavitiya Kanjanavanit, Suparat Prasarakee, Chanidapa Sarachai, Saowalak Taweehorm, Wanvisa Aurpibul, Linda Sintupat, Kamolrawee Khampan, Ratchaneekorn Open Forum Infect Dis Abstracts BACKGROUND: To assess the prevalence and associated factors of protective antibodies against diphtheria, tetanus, and pertussis among HIV-infected adolescents stable on combination antiretroviral treatment (cART). METHODS: A multicenter seroprevalence study was conducted. Perinatally HIV-infected Thai adolescents (11–25 years) who had previous evidence of severely immune suppression (CD4 < 15% or < 200 cells/mm(3)), were currently stable on cART (CD4 > 350 cells/mm(3) for > 6 months or CD4 > 200 cells/mm(3) with viral suppression [VS; HIV RNA < 50 copies/mL] for > 12 months) and had completed a 5-dose series of diphtheria, tetanus, whole cell pertussis (DTwP) vaccine during childhood were enrolled. Adolescents who received immunosuppressive agents or blood components within 6 months were excluded. Protective antibodies for diphtheria, tetanus, and pertussis were defined as diphtheria toxoid IgG ≥ 0.1 IU/mL, tetanus toxoid IgG ≥ 0.1 IU/mL, and anti-pertussis toxin IgG ≥ 5 IU/mL, respectively. Logistic regression analysis was performed to identify factors associated with protective antibody response to each antigen. RESULTS: Of 150 adolescents, 47% were male, a median age was 19 years. Forty (27%) and 0 (0%) adolescents had ever received tetanus, diphtheria (Td) or tetanus, diphtheria, acellular pertussis (Tdap) vaccine during adolescence, respectively. A median duration since the last dose of DTwP/Td vaccine was 12 years. At enrollment, 67% of adolescents were on NNRTI-based cART regimens, a median cART duration was 13 years. A median CD4 was 29%, and 90% had VS. Prevalence of protective antibodies against diphtheria, tetanus, and pertussis were 37%, 82%, and 52%, respectively. Proportion of adolescents with protective antibodies and geometric mean concentrations of antibodies to all antigens declined over time after the last immunization (Figures 1–3). Associated factors of protective antibodies to diphtheria, tetanus and pertussis are shown in Table 1. CONCLUSION: Although having completed a 5-dose series of DTwP during childhood, significant proportion of our perinatally HIV-infected adolescents had no protective antibodies to those antigens, particularly diphtheria and pertussis, when entering adolescence. Tdap vaccination is a crucial strategy to prevent such diseases in the future. [Image: see text] [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810816/ http://dx.doi.org/10.1093/ofid/ofz360.2199 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Sudjaritruk, Tavitiya
Kanjanavanit, Suparat
Prasarakee, Chanidapa
Sarachai, Saowalak
Taweehorm, Wanvisa
Aurpibul, Linda
Sintupat, Kamolrawee
Khampan, Ratchaneekorn
2521. Prevalence and Associated Factors of Protective Antibody Responses against Diphtheria, Tetanus, and Pertussis among HIV-Infected Thai Adolescents Stable on Combination Antiretroviral Treatment
title 2521. Prevalence and Associated Factors of Protective Antibody Responses against Diphtheria, Tetanus, and Pertussis among HIV-Infected Thai Adolescents Stable on Combination Antiretroviral Treatment
title_full 2521. Prevalence and Associated Factors of Protective Antibody Responses against Diphtheria, Tetanus, and Pertussis among HIV-Infected Thai Adolescents Stable on Combination Antiretroviral Treatment
title_fullStr 2521. Prevalence and Associated Factors of Protective Antibody Responses against Diphtheria, Tetanus, and Pertussis among HIV-Infected Thai Adolescents Stable on Combination Antiretroviral Treatment
title_full_unstemmed 2521. Prevalence and Associated Factors of Protective Antibody Responses against Diphtheria, Tetanus, and Pertussis among HIV-Infected Thai Adolescents Stable on Combination Antiretroviral Treatment
title_short 2521. Prevalence and Associated Factors of Protective Antibody Responses against Diphtheria, Tetanus, and Pertussis among HIV-Infected Thai Adolescents Stable on Combination Antiretroviral Treatment
title_sort 2521. prevalence and associated factors of protective antibody responses against diphtheria, tetanus, and pertussis among hiv-infected thai adolescents stable on combination antiretroviral treatment
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810816/
http://dx.doi.org/10.1093/ofid/ofz360.2199
work_keys_str_mv AT sudjaritruktavitiya 2521prevalenceandassociatedfactorsofprotectiveantibodyresponsesagainstdiphtheriatetanusandpertussisamonghivinfectedthaiadolescentsstableoncombinationantiretroviraltreatment
AT kanjanavanitsuparat 2521prevalenceandassociatedfactorsofprotectiveantibodyresponsesagainstdiphtheriatetanusandpertussisamonghivinfectedthaiadolescentsstableoncombinationantiretroviraltreatment
AT prasarakeechanidapa 2521prevalenceandassociatedfactorsofprotectiveantibodyresponsesagainstdiphtheriatetanusandpertussisamonghivinfectedthaiadolescentsstableoncombinationantiretroviraltreatment
AT sarachaisaowalak 2521prevalenceandassociatedfactorsofprotectiveantibodyresponsesagainstdiphtheriatetanusandpertussisamonghivinfectedthaiadolescentsstableoncombinationantiretroviraltreatment
AT taweehormwanvisa 2521prevalenceandassociatedfactorsofprotectiveantibodyresponsesagainstdiphtheriatetanusandpertussisamonghivinfectedthaiadolescentsstableoncombinationantiretroviraltreatment
AT aurpibullinda 2521prevalenceandassociatedfactorsofprotectiveantibodyresponsesagainstdiphtheriatetanusandpertussisamonghivinfectedthaiadolescentsstableoncombinationantiretroviraltreatment
AT sintupatkamolrawee 2521prevalenceandassociatedfactorsofprotectiveantibodyresponsesagainstdiphtheriatetanusandpertussisamonghivinfectedthaiadolescentsstableoncombinationantiretroviraltreatment
AT khampanratchaneekorn 2521prevalenceandassociatedfactorsofprotectiveantibodyresponsesagainstdiphtheriatetanusandpertussisamonghivinfectedthaiadolescentsstableoncombinationantiretroviraltreatment